TrialsgrambetaRCTs are beautiful

STRONG-HF

2022

Safety, Tolerability and Efficacy of Rapid Optimization, helped by NT-proBNP testinG, of Heart Failure therapies

In 1,078 patients recently hospitalised for acute heart failure, rapid up-titration of guideline-directed therapy with close follow-up reduced 180-day death or heart-failure readmission compared with usual care.

Result

Efficacy: 180-day all-cause death or heart-failure readmissionadjusted RR 0.66 (95% CI 0.50-0.86) · P = 0.0021

Below 1 favours rapid up-titration of guideline-directed therapy with close follow-up, above 1 favours usual care.

Event rates
Absolute difference
8.1 points
NNT
13

Absolute difference and NNT are derived from the event rates.

Original publication
Subtopic
GDMT up-titration
Design
Multinational open-label RCT, stopped early for benefit
Relevance
Important: one of several pillars.
Source
Mebazaa A, et al. Lancet. 2022;400(10367):1938-1952.doi 10.1016/S0140-6736(22)02076-1

Discussion & critique

Open-label design and intensive follow-up limit generalisability to routine care, and the primary endpoint was driven largely by HF readmission. Established rapid post-discharge up-titration of GDMT, reinforcing guideline emphasis on early optimisation.

Discussed in podcasts